NCT02287519 Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention Status COMPLETED Phase NA
NCT02287428 Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02282735 Parental Decision-Making for Children With Relapsed Neuroblastoma Status ACTIVE_NOT_RECRUITING Phase N/A
NCT02279394 E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02279004 A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care Status ACTIVE_NOT_RECRUITING Phase N/A
NCT02269982 Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY Status COMPLETED Phase N/A
NCT02269592 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome Status RECRUITING Phase N/A
NCT02269267 The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) Status COMPLETED Phase PHASE2
NCT02268851 A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Status COMPLETED Phase PHASE1
NCT02260531 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Status COMPLETED Phase PHASE2
NCT02257541 BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) Status COMPLETED Phase PHASE1/PHASE2
NCT02251548 A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02244463 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02207504 Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Status COMPLETED Phase PHASE1
NCT02204085 A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Status COMPLETED Phase PHASE1/PHASE2